



# GABA<sub>A</sub> Receptor Subtype Specificity in Essential Tremor

Sheng-Han Kuo<sup>1,2</sup>

Accepted: 31 December 2022 / Published online: 10 February 2023  
© The American Society for Experimental Neurotherapeutics, Inc. 2023

**Keywords** Essential tremor · Tremor · Harmaline · GABA · Alpha6 GABA receptor · Cerebellum · Ethanol

Essential tremor (ET) is a very common neurological disorder, yet it can be highly disabling. People with ET have prominent hand action tremors, causing difficulty with performing activities of daily living such as drinking, eating, handwriting, and typing. Tremor can also involve head and voice in ET. Since ET is an age-related disorder, the prevalence of ET is expected to continue to increase as the worldwide population ages [1]. Therefore, novel therapies for ET are urgently needed.

One interesting clinical observation is that about two-thirds of ET patients experience less tremor after drinking alcohol (i.e., ethanol) [2]. However, how ethanol suppresses tremor in ET remains a mystery, which may have implications for developing new therapies. Ethanol can potentiate  $\gamma$ -aminobutyric acid type A (GABA<sub>A</sub>) receptors [3]; thus, insufficient GABA neurotransmission is considered to be strongly linked to the pathophysiology of ET [4]. This concept is further corroborated by the fact that tremor in some ET patients responds to primidone [5], a form of barbiturate that can increase the duration of GABA<sub>A</sub> receptor opening [6]. It is important to point out that not all ET patients have ethanol or primidone responsiveness, indicating heterogeneity of ET patients.

The key brain areas underlying ET are the cerebellum and the downstream cerebello-thalamo-cortical loop based on ample evidence from neuroimaging [7], neuropathology [8], and animal model studies [9]. There are many different types of synaptic connections in the cerebellum that utilize GABA<sub>A</sub> receptors for inhibitory neurotransmission: (1) Purkinje cells to deep cerebellar nuclear neurons;

(2) interneurons, such as basket cells and stellate cells, to Purkinje cells; and (3) deep cerebellar nuclear neurons to inferior olivary neurons. These locations have been postulated to be sites of ethanol action to suppress tremor in ET [10]. However, GABA<sub>A</sub> receptors are widely expressed throughout the central nervous system; therefore, GABA<sub>A</sub> receptor manipulations are likely to have cognitive side effects such as sedation. Interestingly, ET patients who drink alcohol usually have tremor suppression before they become drunk. Therefore, the tremor-suppressing and sedative effects of ethanol may be via different GABA<sub>A</sub> receptor subtypes at different synaptic or extra-synaptic locations. Understanding GABA<sub>A</sub> receptor subtype specificity in ET will serve as the basis to develop effective therapies for tremor and to minimize side effects.

GABA<sub>A</sub> receptors have complex subtypes, depending on the subunit composition. Each GABA<sub>A</sub> receptor is pentameric containing at least one  $\alpha$  and one  $\beta$  subunits. The common arrangement of GABA<sub>A</sub> receptors is two  $\alpha$  and two  $\beta$  subunits with one  $\gamma$  subunit [11]. Extra-synaptic GABA<sub>A</sub> receptors contain  $\delta$  instead of  $\gamma$  subunit and are particularly enriched in the cerebellum [12]. Granule neurons are the most abundant types of neurons in the cerebellum and express distinctive types of GABA<sub>A</sub> receptors. Specifically,  $\alpha 6\beta 2$  GABA<sub>A</sub> receptors are located at Golgi cell to granule cell synapses, whereas  $\alpha 6\beta \delta$  GABA<sub>A</sub> receptors are situated at the extra-synaptic site [13]. As more small molecules that can target specific subtypes of GABA<sub>A</sub> receptors are being developed, understanding GABA<sub>A</sub> receptor subtype specificity in tremor has become the central focus of ET therapeutic development.

In this issue of Neurotherapeutics, Huang et al. [14] studied the role of the  $\alpha 6$  subunit-containing GABA<sub>A</sub> receptors in tremor. They used the harmaline-induced tremor model in mice. Harmaline can induce action tremor in mice at a frequency between 10 and 16 Hz [15] that is responsive to ethanol and primidone [16], similar to ET patients. They found that a positive allosteric modulator of  $\alpha 6$ GABA<sub>A</sub>

✉ Sheng-Han Kuo  
sk3295@cumc.columbia.edu

<sup>1</sup> Department of Neurology, Columbia University Medical Center, New York, NY, USA

<sup>2</sup> Initiative for Columbia Ataxia and Tremor, Columbia University Irving Medical Center, New York, NY, USA

receptors, called compound 6, or ethanol can effectively suppress harmaline-induced tremor in mice. Interestingly, intracerebellar microinfusion of furosemide ( $\alpha 6$ GABA<sub>A</sub> receptor antagonist, which is clinically used as a diuretic because of its additional function in inhibiting sodium and potassium-2 chloride co-transporters) could partially reverse the effects of ethanol or compound 6 in harmaline-induced tremor. Finally, the authors demonstrated that compound 6 and ethanol synergistically suppress harmaline-induced tremor. These findings are important to help us understand the brain circuitry for tremor. First, activating the  $\alpha 6$  subunit-containing GABA<sub>A</sub> receptors suppresses tremor, which helps us to zoom in on the subtype specificity of GABA<sub>A</sub> receptors. Second, cerebellar microinfusion of a  $\alpha 6$ GABA<sub>A</sub> receptor antagonist can partially reverse the suppressive effects of ethanol and compound 6 in harmaline-induced tremor, which further indicates that  $\alpha 6$ GABA<sub>A</sub> receptors in the cerebellum play a role in tremor. Within the cerebellum, granule cells are likely to be responsible for such effects because  $\alpha 6$ GABA<sub>A</sub> receptors are particularly enriched in these neurons [13]. And finally, since ethanol and compound 6 do not counteract each other's effects on tremor suppression, it is likely that other mechanisms also exist, in addition to  $\alpha 6$ GABA<sub>A</sub> receptor activation. Collectively, these experiments further help us to understand the specific GABA<sub>A</sub> receptor subtypes involved in tremor and have therapeutic implications for ET.

Several limitations and future perspectives should be considered in the context of the current study. First, all the experiments are based on the responses of pharmacological agents (harmaline, ethanol, compound 6, and furosemide); thus, the specificity will need to be further elucidated in the future with genetic approaches. In addition, the pharmacokinetics and pharmacodynamics of each agent are different, which adds to the complexity of the interpretation. Second, while the evidence suggests that granule cells are involved based on the expression of  $\alpha 6$ GABA<sub>A</sub> receptors [13], cell-type-specific manipulations will be needed in the future to confirm this claim. Third, the effects of a  $\alpha 6$ GABA<sub>A</sub> receptor antagonist in blocking the tremor-suppressing effects of compound 6 and ethanol are modest, suggesting that other mechanisms could also be important. And fourth, ET is likely to be a family of diseases with different pathophysiologies [17]. Studying other mouse models of tremor [18, 19] may shed light on the generalizability of the current findings.

It is noteworthy that another GABA<sub>A</sub> receptor subunit has been proposed in the pathophysiology of ET, namely the  $\delta$  subunit. As mentioned above,  $\delta$ GABA<sub>A</sub> receptors are also enriched in the granule cells of the cerebellum, and  $\alpha 6$  and  $\delta$  subunits are often co-expressed as extra-synaptic GABA<sub>A</sub> receptors at the Golgi cell to granule cell synapses [20]. In a harmaline-induced tremor mouse model, activating these extra-synaptic GABA<sub>A</sub> receptors

with gaboxadol suppresses tremor [21]. In addition, gaboxadol failed to suppress tremors in  $\delta$  subunit knockout mice treated with harmaline [21]. These data suggest that the  $\delta$  subunit of GABA<sub>A</sub> receptors can also be a target for ET therapeutic development.

The identification of  $\alpha 6$ GABA<sub>A</sub> receptor involvement in tremor paves the way to further study GABA mechanisms in ET. However,  $\alpha 6$ GABA<sub>A</sub> receptors do not appear to be directly involved in tremor generation, because furosemide microinfusion into the cerebellum does *not* exacerbate harmaline-induced tremor. Rather,  $\alpha 6$ GABA<sub>A</sub> receptors may be an intrinsic circuit mechanism that ethanol or compound 6 can harness to suppress tremors. This is further corroborated by clinical observations that furosemide, when taken as a diuretic by patients, does not appear to worsen or induce tremors. In addition,  $\alpha 6$ GABA<sub>A</sub> receptor knockout mice do not appear to develop tremors either [22]. A similar situation also occurs with  $\delta$  subunit-containing GABA<sub>A</sub> receptors. Genetic deletion of  $\delta$ GABA<sub>A</sub> receptors in mice does not appear to impact harmaline-induced tremor but merely changes the tremor responsiveness to gaboxadol [21]. Of note,  $\delta$ GABA<sub>A</sub> receptor deletion in the cerebellum also does not appear to produce tremor [12].

The harmaline-induced tremor comes from the enhanced coupling of inferior olivary neurons, which entrains the downstream Purkinje cells to fire synchronously and rhythmically via climbing fiber innervation [9]. Much of the literature demonstrates the importance of the inferior olive-Purkinje cell-deep cerebellar nucleus loop in harmaline-induced tremor [10]. The current study by Huang et al. [14] suggests that the granule cells-parallel fiber system can modulate the brain circuitry of tremor. Further exploration of the detailed mechanism of the interactions of climbing fiber and parallel fiber systems, integrated at the Purkinje cells, is likely to yield a more complete picture of ET pathophysiology.

## References

1. Louis ED, McCreary M. How common is essential tremor? Update on the worldwide prevalence of essential tremor. *Tremor Other Hyperkinet Mov.* 2021;11:28.
2. Lou JS, Jankovic J. Essential tremor: clinical correlates in 350 patients. *Neurology.* 1991;41:234–8.
3. Förster B, Castro PA, Moraga-Cid G, Aguayo LG. Potentiation of gamma aminobutyric acid receptors (GABAAR) by ethanol: how are inhibitory receptors affected? *Front Cell Neurosci.* 2016;10:114.
4. Kuo SH, Louis ED. The future of pharmacotherapies for essential tremor: enhancing GABA neurotransmission or reducing neuronal hyperexcitability? *Int Rev Neurobiol.* 2022;163:311–5.
5. Zesiewicz TA, Kuo SH. Essential tremor. *BMJ. Clin Evid.* 2015;2015:1206.
6. Ondo W. Enhancing GABA inhibition is the next generation of medications for essential tremor. *Int Rev Neurobiol.* 2022;163:317–34.

7. van den Berg KRE, Helmich RC. The role of the cerebellum in tremor - evidence from neuroimaging. *Tremor Other Hyperkinet Mov.* 2021;11:49.
8. Louis ED, Faust PL. Essential tremor pathology: neurodegeneration and reorganization of neuronal connections. *Nat Rev Neurol.* 2020;16:69–83.
9. Pan MK, Ni CL, Wu YC, Li YS, Kuo SH. Animal models of tremor: relevance to human tremor disorders. *Tremor Other Hyperkinet Mov.* 2018;8:587.
10. Pan MK, Kuo SH. Essential tremor: clinical perspectives and pathophysiology *J Neurol Sci.* 2022;435:120198.
11. Martenson JS, Yamasaki T, Chaudhury NH, Albrecht D, Tomita S. Assembly rules for GABAA receptor complexes in the brain. *Elife.* 2017;6:e27443.
12. Rudolph S, Guo C, Pashkovski SL, Osorno T, Gillis WF, Krauss JM, Nyitrai H, Flaquer I, El-Rifai M, Datta SR, Regehr WG. Cerebellum-specific deletion of the GABA<sub>A</sub> receptor  $\delta$  subunit leads to sex-specific disruption of behavior. *Cell Rep.* 2020;33:108338.
13. Sieghart W, Chiou LC, Ernst M, Fabjan J, M Savić M, Lee MT.  $\alpha 6$ -containing GABA<sub>A</sub> receptors: functional roles and therapeutic potentials. *Pharmacol Rev.* 2022;74:238–270.
14. Huang YH, Lee MT, Hsueh HY, Knutson DE, Cook J, Mihovilovic MD, Sieghart W, Chiou LC. Cerebellar  $\alpha 6$ GABAA receptors as a therapeutic target for essential tremor: proof-of-concept study with ethanol and pyrazoloquinolones. *Neurotherapeutics*, in this issue.
15. Cheng MM, Tang G, Kuo SH. Harmaline-induced tremor in mice: videotape documentation and open questions about the model. *Tremor Other Hyperkinet Mov.* 2013 Dec 9;3:tre-03–205–4668–1.
16. Paterson NE, Malekiani SA, Foreman MM, Olivier B, Hanania T. Pharmacological characterization of harmaline-induced tremor activity in mice. *Eur J Pharmacol.* 2009;616:73–80.
17. Louis ED, Kuo SH. What's in a name? Nomenclature of essential tremor: syndrome or family of diseases? *Int Rev Neurobiol.* 2022;163:1–5.
18. Pan MK, Li YS, Wong SB, Ni CL, Wang YM, Liu WC, Lu LY, Lee JC, Cortes EP, Vonsattel JG, Sun Q, Louis ED, Faust PL, Kuo SH. Cerebellar oscillations driven by synaptic pruning deficits of cerebellar climbing fibers contribute to tremor pathophysiology. *Sci Transl Med.* 2020;12:eaay1769.
19. Nietz A, Krook-Magnuson C, Gutierrez H, Klein J, Sauve C, Hoff I, Christenson Wick Z, Krook-Magnuson E. Selective loss of the GABA $\alpha$ 1 subunit from Purkinje cells is sufficient to induce a tremor phenotype. *J Neurophysiol.* 2020;124:1183–2119.
20. Nusser Z, Sieghart W, Stephenson FA, Somogyi P. The alpha 6 subunit of the GABAA receptor is concentrated in both inhibitory and excitatory synapses on cerebellar granule cells *J Neurosci.* 1996;16:103–14.
21. Handforth A, Kadam PA, Kosoyan HP, Eslami P. Suppression of harmaline tremor by activation of an extrasynaptic GABAA receptor: implications for essential tremor. *Tremor Other Hyperkinet Mov.* 2018;8:546.
22. Homanics GE, Ferguson C, Quinlan JJ, Daggett J, Snyder K, Lagenaur C, Mi ZP, Wang XH, Grayson DR, Firestone LL. Gene knockout of the alpha6 subunit of the gamma-aminobutyric acid type A receptor: lack of effect on responses to ethanol, pentobarbital, and general anesthetics. *Mol Pharmacol.* 1997;51:588–96.

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.